RENOVACOR INC (RCOR) Stock Price & Overview
NYSEARCA:RCOR • US75989E1064
Current stock price
The current stock price of RCOR is 3.2 USD. Today RCOR is up by 4.92%. In the past month the price increased by 4.92%. In the past year, price decreased by -61.86%.
RCOR Key Statistics
- Market Cap
- 55.262M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.20
- Dividend Yield
- N/A
RCOR Stock Performance
RCOR Stock Chart
RCOR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RCOR. When comparing the yearly performance of all stocks, RCOR is one of the better performing stocks in the market, outperforming 90.69% of all stocks.
RCOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCOR. While RCOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
RCOR Earnings
RCOR Forecast & Estimates
11 analysts have analysed RCOR and the average price target is 7.13 USD. This implies a price increase of 122.73% is expected in the next year compared to the current price of 3.2.
RCOR Groups
Sector & Classification
RCOR Financial Highlights
Over the last trailing twelve months RCOR reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS increased by 48.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.84% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RCOR Ownership
RCOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RCOR
Company Profile
Renovacor, Inc. operates as a clinical stage gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2020-04-24. The firm is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The firm's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The firm is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company’s preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.
Company Info
IPO: 2020-04-24
RENOVACOR INC
201 Broadway, Suite 310
Cambridge MASSACHUSETTS US
CEO: Jonas Grossman
Employees: 19
Phone: 16104242650.0
RENOVACOR INC / RCOR FAQ
What does RCOR do?
Renovacor, Inc. operates as a clinical stage gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2020-04-24. The firm is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The firm's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The firm is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company’s preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.
Can you provide the latest stock price for RENOVACOR INC?
The current stock price of RCOR is 3.2 USD. The price increased by 4.92% in the last trading session.
Does RENOVACOR INC pay dividends?
RCOR does not pay a dividend.
What is the ChartMill rating of RENOVACOR INC stock?
RCOR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of RENOVACOR INC (RCOR)?
RENOVACOR INC (RCOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).